David L Veenstra

List of Publications by Year
in descending order

76 papers	4,744 citations	186265 28 h-index	95266 68 g-index
77 all docs	77 docs citations	77 times ranked	5440 citing authors

#	Article	IF	Citations
1	Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin Dose. New England Journal of Medicine, 2005, 352, 2285-2293.	27.0	1,348
2	Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy. JAMA - Journal of the American Medical Association, 2002, 287, 1690.	7.4	907
3	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	6.2	342
4	Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenetics and Genomics, 2005, 15, 687-691.	1.5	155
5	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	6.2	137
6	The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations. American Journal of Human Genetics, 2018, 103, 319-327.	6.2	122
7	Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2015, 33, 2084-2091.	1.6	118
8	Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genetics in Medicine, 2019, 21, 1100-1110.	2.4	111
9	The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genetics in Medicine, 2015, 17, 587-595.	2.4	101
10	Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemporary Clinical Trials, 2013, 34, 1-9.	1.8	84
11	A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice. Genetics in Medicine, 2010, 12, 686-693.	2.4	83
12	Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. Cmaj, 2015, 187, E190-E197.	2.0	76
13	The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Nonâ€“Small-Cell Lung Cancer. Value in Health, 2009, 12, 20-27.	0.3	74
14	Return of incidental findings in genomic medicine: measuring what patients valueâ€”development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genetics in Medicine, 2013, 15, 873-881.	2.4	72
15	Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?. Genetics in Medicine, 2005, 7, 380-389.	2.4	62
16	Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genetics in Medicine, 2014, 16, 727-735.	2.4	60
17	Economic analyses of human genetics services: A systematic review. Genetics in Medicine, 2005, 7, 519-523.	2.4	52
18	Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genetics in Medicine, 2013, 15, 14-24.	2.4	46

#	Article	IF	Citations
19	The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007). Contemporary Clinical Trials, 2012, 33, 1117-1123.	1.8	45
20	Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 939-947.	0.9	44
21	Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. JAMA Network Open, 2020, 3, e2022874.	5.9	44
22	The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. Journal of Genetic Counseling, 2019, 28, 477-490.	1.6	39
23	Cytochrome P450 Enzyme Polymorphism Frequency in Indigenous and Native American Populations: A Systematic Review. Public Health Genomics, 2008, 11, 141-149.	1.0	36
24	Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics. Medical Decision Making, 2013, 33, 463-471.	2.4	35
25	Precision Medicine, Genome Sequencing, and Improved Population Health. JAMA - Journal of the American Medical Association, 2018, 319, 1979.	7.4	35
26	The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer, 2005, 104, 2054-2062.	4.1	29
27	How Comparative Effectiveness Research Can Help Advance â€˜Personalized Medicineâ€™ In Cancer Treatment. Health Affairs, 2011, 30, 2259-2268.	5.2	28
28	Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. Health Services Research, 2019, 54, 1055-1064.	2.0	28
29	Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Medical Decision Making, 2016, 36, 641-651.	2.4	25
30	Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis. Value in Health, 2020, 23, 96-103.	0.3	25
31	Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned. Journal of Personalized Medicine, 2013, 3, 288-305.	2.5	22
32	Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study. Pharmacoeconomics, 2020, 38, 57-68.	3.3	22
33	Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1210-1217.	0.9	21
34	Harmonizing Outcomes for Genomic Medicine: Comparison of eMERGE Outcomes to ClinGen Outcome/Intervention Pairs. Healthcare (Switzerland), 2018, 6, 83.	2.0	18
35	Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities. Value in Health, 2022, 25, 331-339.	0.3	18
36	Stakeholder Perspectives on a Risk-Benefit Framework for Genetic Testing. Public Health Genomics, 2011, 14, 59-67.	1.0	17

#	Article	IF	Citations
37	Comparative effectiveness of next generation genomic sequencing for disease diagnosis: Design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemporary Clinical Trials, 2014, 39, 1-8.	1.8	17
38	Research Directions in Genetic Predispositions to Stevensâ€“Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology and Therapeutics, 2018, 103, 390-394.	4.7	15
39	Do cancer treatments have option value? Realâ€world evidence from metastatic melanoma. Health Economics (United Kingdom), 2019, 28, 855-867.	1.7	15
40	VKORC 1 and Novel CYP 2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clinical and Translational Science, 2019, 12, 312-320.	3.1	15
41	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics, 2018, 36, 1463-1473.	3.3	14
42	Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment. European Journal of Human Genetics, 2018, 26, 1257-1265.	2.8	14
43	How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health, 2019, 22, 777-784.	0.3	14
44	Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Research in Social and Administrative Pharmacy, 2020, 16, 1033-1040.	3.0	13
45	Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States. Genetics in Medicine, 2022, 24, 1017-1026.	2.4	13
46	A Framework for Prioritizing Research Investments in Precision Medicine. Medical Decision Making, 2016, 36, 567-580.	2.4	12
47	What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?. Patient Education and Counseling, 2021, 104, 726-731.	2.2	11
48	The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant. Journal of Medical Economics, 2017, 20, 453-463.	2.1	8
49	Health Economics Tools and Precision Medicine: Opportunities and Challenges. Forum for Health Economics and Policy, 2020, 23, .	0.8	8
50	Prevalence and prediction of medical distrust in aÂdiverse medical genomic research sample. Genetics in Medicine, 2022, 24, 1459-1467.	2.4	7
51	Cost-effectiveness of population genomic screening. Genetics in Medicine, 2019, 21, 2840-2841.	2.4	6
52	Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study. Contemporary Clinical Trials, 2019, 84, 105820.	1.8	6
53	A Novel LCâ€MS/MS Assay for Quantification of Desâ€carboxy Prothrombin and Characterization of Warfarinâ€Induced Changes. Clinical and Translational Science, 2020, 13, 718-726.	3.1	6
54	Bringing genomics to the bedside. Pharmacogenetics and Genomics, 2004, 14, 333-334.	5.7	5

#	Article	IF	Citations
55	Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome. Journal of Genetic Counseling, 2016, 25, 515-519.	1.6	5
56	Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leukemia and Lymphoma, 2019, 60, 1668-1676.	1.3	5
57	Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. Value in Health, 2021, 24, 1746-1753.	0.3	5
58	A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learningâ€“Based Risk Prediction Models. Value in Health, 2022, 25, 350-358.	0.3	5
59	Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). Journal of Managed Care & Specialty Pharmacy, 2015, 21, 700-712.	0.9	4
60	Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. Journal of Medical Economics, 2018, 21, 960-967.	2.1	4
61	Assessing Payersâ€™ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment. Value in Health, 2022, 25, 443-450.	0.3	4
62	Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. Pharmacogenomics Journal, 2022, 22, 188-197.	2.0	4
63	A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. Value in Health, 2022, 25, 1878-1884.	0.3	4
64	Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2017, 1, 1-13.	3.0	3
65	Reimbursement for genetic variant reinterpretation: five questions payers should ask. American Journal of Managed Care, 2021, 27, e336-e338.	1.1	3
66	Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. Pharmacoeconomics, 2022, 40, 623-631.	3.3	3
67	Developing the Value Proposition for Personalized Medicine. , 2017, , 327-342.		2
68	Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. Value in Health, 2019, 22, 988-994.	0.3	2
69	Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment. Personalized Medicine, 2020, 17, 389-398.	1.5	2
70	The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer. Cancer Causes and Control, 2021, 32, 483-492.	1.8	2
71	Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study. Clinical Ophthalmology, 2021, Volume 15, 453-460.	1.8	2
72	Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry. Molecular Genetics & Genomic Medicine, 2017, 5, 700-708.	1.2	1

#	Article	IF	Citations
73	Relationship between genetic knowledge and familial communication of CRC risk and intent to communicate CRCP genetic information: insights from FamilyTalk eMERGE III. Translational Behavioral Medicine, 2021, 11, 563-572.	2.4	1
74	Real-world evidence for option value in metastatic melanoma. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1-10.	0.9	1
75	Response to Phillips et al.. Genetics in Medicine, 2015, 17, 315-315.	2.4	0
76	Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 615-624.	0.9	0